Filter posts

Why Concerns About a “Break Down” in Drug Pricing Are Misplaced

Just moments after it was announced the FDA had approved a new treatment for spinal …

Dr. Emanuel Misses the Mark with Latest Industry Attack

Writing for The Atlantic, Dr. Ezekiel Emanuel accuses the biopharmaceutical industry of being “deceptive” when …

Two New Infographics Illustrate the Success of the Orphan Drug Act

In recognition of Rare Disease Day, BIO’s Jim Greenwood shared commentary on LinkedIn celebrating the …

Why We Need Innovation in Food and Agriculture

Two of our most beloved breakfast beverages — coffee and orange juice — are under …

Latest Measles Outbreak is a Crash Course on the Importance of Immunization

It’s hard to miss the news coming from the Pacific Northwest. Every major media outlet …

Greenwood Shines Spotlight on Insurance Industry Rip-off

Writing for The Hill, BIO’s President and CEO Jim Greenwood shined a spotlight on a …

The Right Way to Address Prescription Drug Costs

Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City …

Greenwood Talks Innovation, Drug Pricing, and the Midterm Elections on ForbesBooks Radio

During the Forbes Healthcare Summit, BIO CEO Jim Greenwood joined Gregg Stebben, host of ForbesBooks …

Greenwood Highlights Role of Innovation in Solving Opioid Crisis

The numbers are staggering. The opioid epidemic is costing our nation more than $500 billion annually in …

Senate Has the Power to Expand Access to Medication for Opioid Addiction

BIO President and CEO Jim Greenwood posted the following op-ed on Linked-In today, making the …